IMJUDO
Biological
AstraZeneca Pharmaceuticals LP
Total Payments
$3.4M
Transactions
451
Doctors
222
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.3M | 261 | 120 |
| 2023 | $61,451 | 171 | 118 |
| 2022 | $2,046 | 19 | 19 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 2 | 97.5% |
| Consulting Fee | $74,599 | 64 | 2.2% |
| Food and Beverage | $9,564 | 384 | 0.3% |
| Travel and Lodging | $481.09 | 1 | 0.0% |
Payments by Type
Research
$3.3M
2 transactions
General
$84,644
449 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II Single Arm Study of Tremelimumab and Durvalumab T300 D in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis STRIDE in CP-B | AstraZeneca Pharmaceuticals LP | $2.8M | 0 |
| A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma | AstraZeneca Pharmaceuticals LP | $477,360 | 0 |
Top Doctors Receiving Payments for IMJUDO — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | New York, NY | $66.02 | 2 |
| , NP | Family | Tyler, TX | $64.41 | 3 |
| , M.D | Medical Oncology | Dallas, TX | $62.90 | 3 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $61.37 | 3 |
| , MD | Medical Oncology | Tyler, TX | $60.81 | 4 |
| , M.D | Medical Oncology | Dallas, TX | $55.01 | 2 |
| , M.D | Radiation Oncology | Houston, TX | $49.02 | 2 |
| , M.D | Body Imaging | San Diego, CA | $46.52 | 2 |
| , M.D., PH.D | Hematology & Oncology | La Jolla, CA | $46.52 | 2 |
| , M.D | Vascular & Interventional Radiology | San Diego, CA | $46.52 | 2 |
| , M.D | Hematology & Oncology | Tyler, TX | $46.42 | 2 |
| , APRN, FNP-C | Family | Tyler, TX | $45.99 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | Longview, TX | $45.62 | 3 |
| Chelsea White | Acute Care | Tyler, TX | $42.51 | 2 |
| , MD | Radiation Oncology | Tyler, TX | $41.72 | 2 |
| , M.D | Student in an Organized Health Care Education/Training Program | New Orleans, LA | $41.41 | 1 |
| , MD | Internal Medicine | Houston, TX | $41.13 | 2 |
| , PA-C | Physician Assistant | Mckinney, TX | $41.02 | 1 |
| , MD | Hematology & Oncology | Thornton, CO | $40.89 | 2 |
| , M.D | Surgery | Dallas, TX | $40.66 | 1 |
| , M.D | Hematology & Oncology | Sugar Land, TX | $40.66 | 1 |
| , AGNP | Gerontology | Dallas, TX | $40.66 | 1 |
| , M.D | Surgery | Houston, TX | $40.66 | 1 |
| , M.D | Obstetrics & Gynecology | Tyler, TX | $40.28 | 2 |
| , M.D | Hematology & Oncology | Tyler, TX | $40.06 | 2 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $3.4M
- AstraZeneca UK Limited $1,388
Product Information
- Type Biological
- Total Payments $3.4M
- Total Doctors 222
- Transactions 451
About IMJUDO
IMJUDO is a biological associated with $3.4M in payments to 222 healthcare providers, recorded across 451 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2022 to 2024. In 2024, $3.3M was paid across 261 transactions to 120 doctors.
The most common payment nature for IMJUDO is "Unspecified" ($3.3M, 97.5% of total).
IMJUDO is associated with 2 research studies, including "Phase II Single Arm Study of Tremelimumab and Durvalumab T300 D in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis STRIDE in CP-B" ($2.8M).